TL;DR
A CRO insurance program is structured around three coverages: professional liability and E&O sized to sponsor MSA scope (with no clinical-trial-work exclusion), cyber liability sized to PHI dataset volume (not headcount), and a coordination boundary between the CRO E&O and sponsor clinical trial liability. Pre-clinical CROs scale lower, late-stage CROs with EU sites scale materially higher.
Contract Research Organizations · Texas
Professional liability and errors and omissions, written on the right form for clinical or pre-clinical research services. Cyber liability sized for the volume of PHI and sponsor-confidential data your operation actually handles. Clinical trial liability - when sponsor MSAs unusually push the obligation onto the CRO instead of the sponsor.
The fourth conversation, less often discussed, is what happens at the boundary between your E&O and your sponsor's clinical trial liability when a subject injury claim arises. Coordination there is the difference between a clean sponsor relationship and a coverage fight.
Problem 01 · Professional liability scope
Many generic E&O policies carry exclusions for clinical trial work because the underwriting was originally written for tech consultants and traditional professional services. A CRO operating under that form discovers at first claim that protocol monitoring errors, source document review failures, and protocol deviation reporting failures are not covered.
The fix is verifying the policy form explicitly includes clinical trial monitoring scope, or moving to a specialty CRO E&O carrier. Sponsor MSAs increasingly require the CRO to represent that its E&O covers clinical trial work; an exclusion in the underlying policy creates a contractual misrepresentation risk in addition to the coverage gap.
Problem 02 · Cyber sizing
A 50-employee CRO supporting a 2,000-subject Phase 3 trial faces breach exposure proportional to the 2,000 subjects, not to the 50 employees. Most generalist cyber programs are sized to headcount and revenue, which materially under-sizes the actual PHI exposure.
Late-stage clinical CROs with EU site exposure require GDPR-aligned cyber and EU breach notification capability. Pre-clinical bioanalytical CROs scale lower because the data is animal-subject data, but cGLP-aligned property and validation losses become load-bearing.
Problem 03 · CTL boundary
A subject injury claim arising from a protocol deviation can plausibly fall under the sponsor's clinical trial liability or the CRO's professional liability depending on cause. When the boundary is not explicit in the contracts and policies, both carriers can deny while the operator is exposed.
Best-practice CTAs and MSAs include explicit coordination language and stipulated triggers. Where they do not, the program structure should anticipate the coordination question by aligning policy forms and carriers that have worked together before.
Problem 04 · Contingent vendor cyber
CRO vendor stack breaches (eTMF hosts, EDC vendors, central labs) are the most common breach vector that triggers downstream sponsor MSA cyber response obligations. Standard cyber policies do not always include contingent vendor coverage by default.
Sponsor MSAs in 2026 increasingly require explicit contingent cyber coverage covering the CRO's vendor stack. Verify the policy form addresses this scope before signing the next sponsor MSA.
Carrier access
Generalist carriers will write a CRO and price it as a tech consulting firm. The placement looks fine on the COI. The placement falls apart at first claim, when it turns out the E&O excluded clinical trial work, or the cyber was sized to headcount instead of dataset.
Our placements run through carriers with dedicated life-sciences and clinical research underwriting and, where appropriate, EU-extension placements for CROs with European site exposure. We know which markets write Phase 1-only differently than Phase 3 with EU sites.
Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.
Pricing
Premium ranges for clinical and pre-clinical CROs at $5M-$50M revenue, the factors that drive cost, and sample programs across clinical phases.
Clusters served
We place programs for Texas-based clinical and pre-clinical CROs and for CRO-sponsor relationships in the broader national footprint: Massachusetts, North Carolina (RTP), and California. CRO programs frequently coordinate with sponsor clinical trial liability, bioanalytical laboratory insurance, and pathology liability coverage for in-house central lab operations.
The MSA Decoder tool covers CRO-relevant clauses end-to-end - clinical trial liability, professional liability, cyber, sponsor indemnity boundary - so a sponsor MSA can be read in half an hour.
Frequently asked
Three coverages cover most sponsor MSA requirements: professional liability and errors & omissions written for clinical or pre-clinical research services; cyber liability sized for the volume of PHI and sponsor-confidential data; and clinical trial liability when the MSA pushes that obligation to the CRO. General liability is also required but rarely the friction point.
No. E&O covers errors in services (study design, data analysis, regulatory submission errors). Products liability covers physical harm from a manufactured product. CROs need E&O; CDMOs need products. Some hybrid CRO/CDMO operations need both.
Most clinical CROs carry $3M to $10M cyber, sized to the number of subjects, the sensitivity of PHI handled, and any sponsor-required minimums. Diagnostic and bioanalytical labs often need higher limits because of HIPAA exposure.
The sponsor is typically the named insured on the trial-liability policy and the CRO is added as additional insured. The boundary fight happens when a subject injury claim alleges study-design or protocol-execution failure - that can land in the CRO's E&O instead of the sponsor's clinical trial coverage. Coordination language in the MSA and on the COI determines who pays first.
No. Pre-clinical / GLP toxicology work on animals does not require clinical trial liability. Animal-care liability (often a rider on GL) covers the animal subjects. E&O covers data integrity and study design.
Same-day to 5 business days for most carriers. Blanket additional-insured endorsements that auto-add anyone you contract with are available on most pharma-friendly E&O forms.
Next steps
Sponsor-side clinical trial liability - what it covers, limits by phase, EU CTR placement, and the sponsor-CRO boundary.
OpenPhase + sites + enrollment + geography + indication returns a clinical trial liability coverage-need band.
OpenFive cyber program structures for clinical and pre-clinical CROs - sized to PHI volume, not headcount.
OpenFive CRO professional liability and E&O architectures by clinical phase, geographic scope, and service category.
OpenAuthoritative references
The harmonized GCP standard governing sponsor/CRO/site responsibilities in clinical trials.
FDA inspection program covering CROs, sponsors, IRBs, and clinical investigators.
IND regulations governing sponsor obligations the CRO often inherits via MSA.
PHI handling requirements that drive CRO cyber liability sizing.
Validation standard for clinical data systems - sponsor audits routinely test compliance.
Why operators choose this practice
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Related deep-dives
CRO coverage review
No marketing sequences, no list rental. Half-hour MSA reads are the standard.